Our primary objective is to fast-track the application of innovative medical technologies and biological ideas originating from PRIMA into clinical practice.
This includes the introduction of groundbreaking CRISPR strategies and the precision enhancement of primary T and NK cells. These cells can be sourced from the patient for a more personalized therapy, or from third-party donors for broader treatment methods.
Additionally, we're planning to harness the limitless self-renewal capabilities of iPSCs to produce the next wave of iPSC-derived NK/T cells, suitable for ready-to-use cell therapies. To assess the biological characteristics and treatment potential of these new cell therapy products and protein biologics, we'll employ sophisticated 3D in vitro models and humanized mice. They can be tested alone or in combination.
The most promising ideas will then be further transformed into pre-GMP protocols. We will take full advantage of the GMP expertise found within the newly established ACT Center at OUH for this crucial process.
